RSRobert L. Sielken

Robert L. Sielken

*This is an algorithmically generated author record based on publicly available information.

Robert L. Sielken has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cancer Dose‐Response Modeling of Epidemiological Data on Worker Exposures to Aldrin and Dieldrin

    by Robert L. Sielken, Robert S. Bretzlaff, Ciriaco Valdez‐Flores, Donald E. Stevenson, Geed de Jong

    The paper applies classical statistical principles to yield new tools for risk assessment and makes new use of epidemiological data for human riskassessment. An extensive clinical and epidemiological study of workers engaged in the manufacturing and formulation of aldrin and dieldrin provides occupational hygiene and biological monitoring data on individual exposures over the years of employment and provides unusually accurate measures of individual lifetime average daily doses. In the cancer dose‐response modeling, each worker is treated as a separate experimental unit with his own unique dose. Maximum likelihood estimates of added cancer risk are calculated for multistage, multistage‐Weibull, and proportional hazards models. Distributional characterizations of added cancer risk are based on bootstrap and relative likelihood techniques. The cancer mortality data on these male workerssuggest that low‐dose exposures to aldrin and dieldrin do not significantlyincrease human cancer risk and may even decrease the human hazard rate for all types of cancer combined at low doses (e.g., 1μg/kg/day). The apparent hormetic effect in the best fitting dose‐response models for this data set is statistically significant. The decrease in cancer risk at low doses ofaldrin and dleldrin is in sharp contrast to the U.S. Environmental Protection Agency's upper bound on cancer potency based on mouse liver tumors. The EPA's upper bound implies that lifetime average daily doses of 0.0000625 and 0.00625 pμg/kg body weight/day would correspond to increased cancer risks of 0.000001 and O.OOO1, respectively. However, the best estimate from the Pernis epidemiological data is that there is no increase in cancer risk in these workers at these doses or even at doses as large as 2 μg/kg/day.


  • Cancer dose-response modeling of epidemiological data on worker exposures to aldrin and dieldrin.

    by R L Sielken, R S Bretzlaff, C Valdez-Flores, D E Stevenson, G de Jong

    The paper applies classical statistical principles to yield new tools for risk assessment and makes new use of epidemiological data for human risk assessment. An extensive clinical and epidemiological study of workers engaged in the manufacturing and formulation of aldrin and dieldrin provides occupational hygiene and biological monitoring data on individual exposures over the years of employment and provides unusually accurate measures of individual lifetime average daily doses. In the cancer dose-response modeling, each worker is treated as a separate experimental unit with his own unique dose. Maximum likelihood estimates of added cancer risk are calculated for multistage, multistage-Weibull, and proportional hazards models. Distributional characterizations of added cancer risk are based on bootstrap and relative likelihood techniques. The cancer mortality data on these male workers suggest that low-dose exposures to aldrin and dieldrin do not significantly increase human cancer risk and may even decrease the human hazard rate for all types of cancer combined at low doses (e.g., 1 microgram/kg/day). The apparent hormetic effect in the best fitting dose-response models for this data set is statistically significant. The decrease in cancer risk at low doses of aldrin and dieldrin is in sharp contrast to the U.S. Environmental Protection Agency's upper bound on cancer potency based on mouse liver tumors. The EPA's upper bound implies that lifetime average daily doses of 0.0000625 and 0.00625 microgram/kg body weight/day would correspond to increased cancer risks of 0.000001 and 0.0001, respectively. However, the best estimate from the Pernis epidemiological data is that there is no increase in cancer risk in these workers at these doses or even at doses as large as 2 micrograms/kg/day.


  • Open Access

    Modeling to incorporate defense mechanisms into the estimation of dose responses.

    by R L Sielken, D E Stevenson

    Several adverse health effects (including cancer and noncancer effects) may be the result of an imbalance between exogenous and endogenous invading substances and defense mechanisms. In these cases the probability of an adverse effect depends on how much the exposure to a substance increases or decreases the number of defenders or their efficiency as well as increasing or decreasing the number of invaders. Rather than using a dose scale such as parts per million or milligram/kilogram/day in these cases, dose-response models can directly incorporate the impact of defense mechanisms by using a dose scale that corresponds to the number of invaders that break through the defenders and become free to do their damage. The number of breakthroughs at a specific age, the cumulative number of breakthroughs by a specific age, or the cumulative number of breakthroughs in a window of time would usually be the appropriate age-dependent dose. Although a lifetime average daily dose level can be used as a surrogate for an age-dependent dose in simplistic dose-response models, the age-dependent dose itself can be used in more biologically based models that include time, reflect the key role of feedback mechanisms, and treat the human body as an age-dependent dynamic system responding to internal and external stimuli and not as a system at equilibrium. Some illustrative biologic examples of defense mechanisms and invader-defender interactions are presented. Several numerical examples are given in which the dose incorporates the age-dependent effects of a substance on the number of invaders, the number of defenders, and/or the defenders' efficiencies.


    • 1 January 1994
      • Vol. 387, 237-60

    Incorporating additional biological phenomena into two-stage cancer models.

    by R L Sielken, R S Bretzlaff, D E Stevenson

    Several difficulties arise in the implementation of the Armitage-Doll-type carcinogenesis model. Some of these difficulties have been briefly discussed herein, with particular attention to the recent finding that the magnitude of current animal-based bounds on human cancer potency is influenced by animal background transition rates. Although the ideal method of accounting for the background transition rates necessitates more direct biological information, this paper offers risk assessors some alternatives for improving current quantitative cancer potency assessment. Computer software has been developed to facilitate the use of not only the multistage model but also other dose-response models, including the following: 1) tolerance models (probit, logit, multihit, and Weibull), which assume that a distribution of tolerances exists in the population and that when a tolerance is exceeded, a carcinogenic response occurs; 2) multihit models, which assume that a carcinogenic response occurs when a tissue receives more than a specified number of hits; 3) Armitage-Doll multistage models, which explicitly model the time and/or dose dependence of each transition stage; 4) time-to-response extensions of the multistage model; and 5) extensions of the multistage model including cell proliferation (Lu and Sielken 1991, Holland and Sielken 1993). In any of the dose-response models, the dose scale is not restricted to the administered dose scale. Computer software that facilitates the use of more biologically relevant dose scales (such as delivered and biologically effective dose scales) is now available. Furthermore, the differences between species and routes of exposure in the amount of delivered or biologically effective dose corresponding to a particular administered dose can be incorporated. The dependence of an individual's dose on not only the individual's administered dose but also the individual's background dose and susceptibility can be incorporated as well. Hence, interindividual variability in dose levels and probabilities of a carcinogenic response can be considered (Holland and Sielken 1993). The possibility also exists of incorporating more cell biology into carcinogenesis theory using the MVK two-stage model. In this model, cell proliferation parameters are included, in contrast to models of the Armitage-Doll family. The MVK model offers increased potential for obtaining estimates of low-dose behavior that reflect more of the available biological data, including microdosimetry data. A Monte Carlo simulator for this model can be used in cases in which more complex biological mechanisms are included, information other than the means of population distributions is desired, and information on subpopulations is desired.(ABSTRACT TRUNCATED AT 400 WORDS)